- Home
- Publications
- Publication Search
- Publication Details
Title
c-MET kinase inhibitors: a patent review (2011 – 2013)
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 24, Issue 2, Pages 217-230
Publisher
Informa Healthcare
Online
2013-11-25
DOI
10.1517/13543776.2014.864279
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characteristics of Lung Cancers Harboring NRAS Mutations
- (2013) K. Ohashi et al. CLINICAL CANCER RESEARCH
- c-Met inhibitors
- (2013) Anum Mughal et al. Infectious Agents and Cancer
- From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer
- (2012) Isabelle Dussault et al. Anti-Cancer Agents in Medicinal Chemistry
- Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
- (2012) Ted Underiner et al. Anti-Cancer Agents in Medicinal Chemistry
- Network pharmacology for cancer drug discovery: are we there yet?
- (2012) Asfar S Azmi Future Medicinal Chemistry
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
- (2012) K. Ohashi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway
- (2012) Abbas K. Samadi et al. SURGERY
- A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients
- (2011) R. Tiedt et al. CANCER RESEARCH
- A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling
- (2011) Alessandro Furlan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Structural Basis for Selective Small Molecule Kinase Inhibition of Activated c-Met
- (2011) Keith W. Rickert et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Synthesis and c-Met Kinase Inhibition of 3,5-Disubstituted and 3,5,7-Trisubstituted Quinolines: Identification of 3-(4-Acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a Novel Anticancer Agent
- (2011) Yuanxiang Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay
- (2011) Zhongjie Liang et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- From 'omics' to complex disease: a systems biology approach to gene-environment interactions in cancer
- (2010) Sarah S Knox Cancer Cell International
- Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma
- (2010) I. J. Davis et al. CANCER RESEARCH
- Small molecule c-Met kinase inhibitors: a review of recent patents
- (2010) John Porter EXPERT OPINION ON THERAPEUTIC PATENTS
- Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors
- (2009) Sergei L. Timofeevski et al. BIOCHEMISTRY
- Novel Agents on the Horizon for Cancer Therapy
- (2009) W. W. Ma et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
- (2009) L. Liu et al. CANCER RESEARCH
- Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
- (2009) J. P. Eder et al. CLINICAL CANCER RESEARCH
- Discovery ofN-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily
- (2009) Gretchen M. Schroeder et al. JOURNAL OF MEDICINAL CHEMISTRY
- Developing c-MET pathway inhibitors for cancer therapy: progress and challenges
- (2009) Xiangdong Liu et al. TRENDS IN MOLECULAR MEDICINE
- A new Met inhibitory-scaffold identified by a focused forward chemical biological screen
- (2008) Salvatore Patané et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase
- (2008) John Porter et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Identification of a Novel Recepteur d'Origine Nantais/c-Met Small-Molecule Kinase Inhibitor with Antitumor Activity In vivo
- (2008) Y. Zhang et al. CANCER RESEARCH
- Showering c-MET-dependent cancers with drugs
- (2008) Beatrice S. Knudsen et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- NK4 gene therapy targeting HGF-Met and angiogenesis
- (2007) Kunio Matsumoto Frontiers in Bioscience-Landmark
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started